Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Platinum(IV)-Ferrocene Conjugates and Their Cyclodextrin Host-Guest Complexes.

Thiabaud G, Harden-Bull L, Ghang YJ, Sen S, Chi X, Bachman JL, Lynch VM, Siddik ZH, Sessler JL.

Inorg Chem. 2019 Jun 17;58(12):7886-7894. doi: 10.1021/acs.inorgchem.9b00570. Epub 2019 May 24.

PMID:
31125214
2.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G.

EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.

3.

Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights.

Farooqi AA, de la Roche M, Djamgoz MBA, Siddik ZH.

Semin Cancer Biol. 2019 Oct;58:65-79. doi: 10.1016/j.semcancer.2019.01.001. Epub 2019 Jan 8. Review.

PMID:
30633978
4.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

5.

Curcumin-Free Turmeric Exhibits Activity against Human HCT-116 Colon Tumor Xenograft: Comparison with Curcumin and Whole Turmeric.

Prasad S, Tyagi AK, Siddik ZH, Aggarwal BB.

Front Pharmacol. 2017 Dec 12;8:871. doi: 10.3389/fphar.2017.00871. eCollection 2017. Retraction in: Front Pharmacol. 2018 Apr 16;9:400.

6.

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.

Bhatt M, Ivan C, Xie X, Siddik ZH.

Oncotarget. 2017 Feb 14;8(7):10905-10918. doi: 10.18632/oncotarget.14228.

7.

Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.

Xie X, He G, Siddik ZH.

Mol Cancer Res. 2017 Mar;15(3):328-339. doi: 10.1158/1541-7786.MCR-16-0257-T. Epub 2016 Dec 28.

8.

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.

Altaf M, Monim-Ul-Mehboob M, Kawde AN, Corona G, Larcher R, Ogasawara M, Casagrande N, Celegato M, Borghese C, Siddik ZH, Aldinucci D, Isab AA.

Oncotarget. 2017 Jan 3;8(1):490-505. doi: 10.18632/oncotarget.13448.

9.

Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.

Thiabaud G, McCall R, He G, Arambula JF, Siddik ZH, Sessler JL.

Angew Chem Int Ed Engl. 2016 Oct 4;55(41):12626-31. doi: 10.1002/anie.201604236. Epub 2016 Jul 5.

10.

Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.

Xie X, Lozano G, Siddik ZH.

Oncogene. 2016 Sep 8;35(36):4798-806. doi: 10.1038/onc.2016.12. Epub 2016 Feb 15.

11.

Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.

Farooqi AA, Siddik ZH.

Cell Biochem Funct. 2015 Jul;33(5):257-65. doi: 10.1002/cbf.3120. Epub 2015 Jul 7. Review.

12.

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.

Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP.

Clin Epigenetics. 2015 Mar 17;7:29. doi: 10.1186/s13148-015-0065-5. eCollection 2015.

13.

Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.

Thiabaud G, Arambula JF, Siddik ZH, Sessler JL.

Chemistry. 2014 Jul 14;20(29):8942-7. doi: 10.1002/chem.201403094. Epub 2014 Jun 24.

14.

Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.

Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH.

Lung Cancer. 2014 Jul;85(1):88-93. doi: 10.1016/j.lungcan.2014.04.005. Epub 2014 Apr 22.

15.

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.

He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH.

Br J Cancer. 2013 Oct 29;109(9):2378-88. doi: 10.1038/bjc.2013.613. Epub 2013 Oct 8.

16.

Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.

Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK.

Neoplasia. 2013 May;15(5):502-10.

17.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

18.

Recent developments in texaphyrin chemistry and drug discovery.

Preihs C, Arambula JF, Magda D, Jeong H, Yoo D, Cheon J, Siddik ZH, Sessler JL.

Inorg Chem. 2013 Nov 4;52(21):12184-92. doi: 10.1021/ic400226g. Epub 2013 Apr 4. Review.

19.

Tissue platinum concentration and tumor response in non-small-cell lung cancer.

Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH.

J Clin Oncol. 2012 Sep 20;30(27):3345-52. doi: 10.1200/JCO.2011.40.8120. Epub 2012 Aug 13.

20.

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Martinez-Rivera M, Siddik ZH.

Biochem Pharmacol. 2012 Apr 15;83(8):1049-62. doi: 10.1016/j.bcp.2011.12.026. Epub 2011 Dec 26. Review.

22.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

23.

The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.

He G, Kuang J, Khokhar AR, Siddik ZH.

Gynecol Oncol. 2011 Aug;122(2):402-9. doi: 10.1016/j.ygyno.2011.04.034. Epub 2011 May 18.

24.

Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.

Arambula JF, Sessler JL, Siddik ZH.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1701-5. doi: 10.1016/j.bmcl.2011.01.092. Epub 2011 Jan 26.

25.

Bismuth- and lead-texaphyrin complexes: towards potential α-core emitters for radiotherapy.

Preihs C, Arambula JF, Lynch VM, Siddik ZH, Sessler JL.

Chem Commun (Camb). 2010 Nov 14;46(42):7900-2. doi: 10.1039/c0cc03528a. Epub 2010 Oct 4.

26.

Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: synthesis and comparison with carboplatin in normal and Pt-resistant cell lines.

Arambula JF, Sessler JL, Fountain ME, Wei WH, Magda D, Siddik ZH.

Dalton Trans. 2009 Dec 28;(48):10834-40. doi: 10.1039/b912089k. Epub 2009 Oct 7.

27.

Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.

Kurokawa T, He G, Siddik ZH.

Cancer Chemother Pharmacol. 2010 Feb;65(3):427-36. doi: 10.1007/s00280-009-1045-2. Epub 2009 Jun 16.

28.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

29.

Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1.

Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT.

Mol Pharmacol. 2008 Sep;74(3):697-704. doi: 10.1124/mol.108.047969. Epub 2008 Jun 3.

30.
31.

Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.

He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH.

Br J Cancer. 2006 Dec 4;95(11):1514-24. Epub 2006 Nov 7.

32.

Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities.

He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR, Kuang J.

Oncogene. 2005 Apr 21;24(18):2929-43.

PMID:
15735718
33.
34.

Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.

Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT.

Mol Cancer Ther. 2004 Dec;3(12):1543-9. Erratum in: Mol Cancer Ther. 2005 May;4(5):864.

35.

Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog.

Mujoo K, Watanabe M, Khokhar AR, Siddik ZH.

Prostate. 2005 Jan 1;62(1):91-100.

PMID:
15389812
36.

Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Siddik ZH.

Oncogene. 2003 Oct 20;22(47):7265-79. Review.

PMID:
14576837
37.

Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH.

J Cancer Res Clin Oncol. 2003 Oct;129(10):549-55. Epub 2003 Aug 29.

PMID:
14513369
38.

Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH.

J Cancer Res Clin Oncol. 2003 Dec;129(12):709-18. Epub 2003 Sep 26.

PMID:
14513366
39.

Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.

Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX.

J Biol Chem. 2003 May 23;278(21):19245-56. Epub 2003 Mar 12.

40.
41.

Biochemical and molecular mechanisms of cisplatin resistance.

Siddik ZH.

Cancer Treat Res. 2002;112:263-84. Review. No abstract available.

PMID:
12481720
42.

Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints.

Kuang J, He G, Huang Z, Khokhar AR, Siddik ZH.

Clin Cancer Res. 2001 Nov;7(11):3629-39.

43.
44.

EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.

Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R.

Clin Cancer Res. 2000 Jan;6(1):193-202.

45.
46.

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB.

Clin Cancer Res. 1999 Dec;5(12):4308-18.

47.

Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance.

Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR.

J Inorg Biochem. 1999 Oct;77(1-2):65-70. Review.

PMID:
10626356
49.

Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model.

Pusztai L, Siddik ZH, Mills GB, Bast RC Jr.

Acta Oncol. 1998;37(7-8):629-40. Review.

PMID:
10050979
50.

Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2].

Shamsuddin S, Santillan CC, Stark JL, Whitmire KH, Siddik ZH, Khokhar AR.

J Inorg Biochem. 1998 Aug;71(1-2):29-35.

PMID:
9755489

Supplemental Content

Loading ...
Support Center